Previous 10 | Next 10 |
SEATTLE, April 12, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that dosing has been initiated in a phase 1 clinical tri...
SEATTLE, April 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Eric Dobmeier, president and chief executive office...
SEATTLE, April 05, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), the IgA Nephropathy Foundation and Komodo Health today announced an outreach initiative leveraging data and technology to drive awareness of Immunoglobulin A (IgA) nephropathy and engage key medic...
Gainers: Burning Rock Biotech Limited (BNR) +5%. Hemisphere Media Group (HMTV) +4%. Neuronetics (STIM) +4%. AvePoint (AVPT) +3%. Jounce Therapeutics (JNCE) +3%. Losers: UroGen Pharma (URGN) -12%. Purple Innovation (PRPL) -5%. Trinity Capital (TRIN) -4%. ...
Baker Brothers’ 13F portfolio value decreased from $22.77B to $20.55B this quarter. Incyte and Legend Biotech stakes were increased this quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~63% of the portfolio. For f...
SEATTLE, March 21, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced the appointment of Mahesh Krishnan, M.D., M.P.H., M.B.A....
Chinook Therapeutics press release (NASDAQ:KDNY): FY GAAP EPS of -$2.26. Revenue of $51.62M (+6195.1% Y/Y). For further details see: Chinook Therapeutics GAAP EPS of -$2.26, revenue of $51.62M
SEATTLE, March 17, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today provided a business update and reported financial results for the ...
SEATTLE, March 08, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to participate in a...
SEATTLE, Feb. 22, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (NASDAQ: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced upcoming presentations at the 4 th Annual Chronic Kid...
News, Short Squeeze, Breakout and More Instantly...
Chinook Therapeutics Inc Com Company Name:
KDNY Stock Symbol:
NASDAQ Market:
Chinook Therapeutics Inc Com Website:
Chinook Therapeutics, Inc. (NASDAQ: KDNY) has caught the attention of the investment community today with its bullish price action. The company's shares are currently up 2.86% on the day to $40.3. Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, dev...
SEATTLE, July 28, 2023 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that the first patient with IgA nephropathy (IgAN) has been enr...
NEW YORK, NY / ACCESSWIRE / July 27, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: Sculptor Capital Management Inc. (NYS...